

JPET #227066

## Title Page

New multi-target antagonists of  $\alpha_{1A}$ ,  $\alpha_{1D}$  adrenoceptors and 5-HT<sub>1A</sub> receptors reduce human hyperplastic prostate cell growth and the increase of intraurethral pressure

Jéssica B Nascimento-Viana, Aline R Carvalho, Luiz Eurico Nasciutti, Rocío Alcántara-Hernández, Fernanda Chagas-Silva, Pedro A R Souza, Luiz Antônio S Romeiro, J Adolfo García-Sáinz, François Noël, and Claudia Lucia Martins Silva

Laboratory of Molecular and Biochemical Pharmacology (JBNV, ARC, FCS, FN, CLMS) and Cell Biology and Development Research Program (PARS, LEN), Universidade Federal do Rio de Janeiro; Cell Physiology Institute (RAH, JAGS), Universidad Nacional Autónoma de México; Pharmaceutical Sciences (LASR), Universidade de Brasília

JPET #227066

**Running title page.**

Running title:

New multi-target drugs as potential leads for BPH treatment

Corresponding author: Claudia Lucia Martins Silva

Laboratory of Molecular and Biochemical Pharmacology, Universidade Federal do Rio de Janeiro. Av Carlos Chagas Filho, 373. Zip code 21941-599, Rio de Janeiro, Brazil.

email: [silva.claudiamartins.ufrj@gmail.com](mailto:silva.claudiamartins.ufrj@gmail.com), [cmartins@farmaco.ufrj.br](mailto:cmartins@farmaco.ufrj.br)

The number of:

Text pages: 48

Tables:3

Figures: 4

References: 73

Number of words in the:

Abstract: 253 words

Introduction: 732 words

Discussion: 1582 words

Abbreviations list:

5-HT	5-Hydroxytryptamine (serotonin)
BPH	Benign prostatic hyperplasia
IUP	Intraurethral pressure
LUTS	Lower urinary tract symptoms
PHE	Phenylephrine
TGF- $\beta$	transforming growth factor $\beta$
TLC	Thin-layer chromatography

Section: Drug Discovery and Translational Medicine

JPET #227066

## Abstract

Benign prostatic hyperplasia (BPH) is characterized by stromal cell proliferation and contraction of the periurethral smooth muscle, causing lower urinary tract symptoms. Current BPH treatment, based on monotherapy with  $\alpha_{1A}$ -adrenoceptor antagonists, is helpful for many patients but insufficient for others, and recent reports suggest that stimulation of  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors contribute to cell proliferation. Here, we investigated the potential of three *N*-phenylpiperazine derivatives - LDT3, LDT5 and LDT8 - as multi-target antagonists of BPH-associated receptors. The affinity and efficacy of LDTs were estimated in isometric contraction and competition binding assays using tissues (prostate and aorta) and brain membrane samples enriched in specific on- or off-target receptors. LDTs potency was estimated in intracellular Ca<sup>2+</sup> elevation assays using cells overexpressing human  $\alpha_1$ -adrenoceptors subtypes. The anti-proliferative effect of LDTs on prostate cells from BPH patients was evaluated by viable cell counting and MTT assays. We also determined LDTs effects on rat intraurethral and arterial pressure. LDT3 and LDT5 are potent antagonists of  $\alpha_{1A}$ -,  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors ( $K_i$  values in the nanomolar range), and fully inhibited phenylephrine- and 5-HT-induced proliferation of BPH cells. *In vivo*, LDT3 and LDT5 fully blocked the increase of intraurethral pressure induced by phenylephrine at doses (ED<sub>50</sub> of 0.15 and 0.09  $\mu\text{g}\cdot\text{kg}^{-1}$ , respectively) without effect on basal mean blood pressure. LDT3 and LDT5 are multi-target antagonists of key receptors in BPH, and are capable of triggering both prostate muscle relaxation and human hyperplastic prostate cell growth inhibition *in vitro*. Thus, LDT3 and LDT5 represent potential new lead compounds for BPH treatment.

JPET #227066

## Introduction

Benign prostatic hyperplasia (BPH) is a progressive disease with considerable impact on the quality of life of a large portion of aging men (Nickel, 2003). The condition stems from an imbalance between cell proliferation and apoptosis (Roehrborn, 2008; Sciarra et al., 2008). Amongst several factors, the proliferation of periurethral prostatic stromal cells and the prostatic smooth muscle contraction contribute to the lower urinary tract symptoms (LUTS) suggestive of BPH (LUTS/BPH) (Roehrborn, 2008).

$\alpha_{1A}$ -Adrenoceptor is the predominant subtype expressed in human prostate, particularly in the stroma (Price et al., 1993; Tseng-Crank et al., 1995) and mediates prostate muscle contraction (Fornay et al., 1994). These receptors are also highly expressed in hyperplastic prostate and, under this condition, their mRNA level corresponds to approximately 85% of the total prostate  $\alpha_1$ -adrenoceptor mRNA content (Nasu et al., 1996).

Both the American and European Urological Associations consider  $\alpha_1$ -adrenoceptor antagonism as an appropriate pharmacological treatment to control moderate to severe LUTS/BPH (McVary et al., 2011; Oelke et al., 2013). Nevertheless, the introduction of  $\alpha_{1A}$ -adrenoceptor antagonists such as tamsulosin, or the uroselective  $\alpha_1$ -adrenoceptor blocker alfuzosin, was a major advance in the management of BPH, mainly due to the better tolerability by patients (Michel 2010; Jelski and Speakman, 2012). However, the pharmacological management of LUTS/BPH by monotherapy with  $\alpha_{1A}$ -adrenoceptor antagonists is helpful for many patients but insufficient for others (Jelski and Speakman, 2012; Perabo, 2012). Two important factors of LUTS/BPH not addressed by  $\alpha_{1A}$ -adrenoceptors blockers are sheer prostate size and detrusor muscle contraction (McVary et al., 2011; Oelke et al., 2013).

JPET #227066

The possibility that  $\alpha_{1D}$ -adrenoceptors also might play a role in the pathogenesis of BPH has been suggested. According to data obtained by RNase protection, *in situ* hybridization or RT-PCR assays, the expression level of  $\alpha_{1A}$ -,  $\alpha_{1B}$ - and  $\alpha_{1D}$ -adrenoceptors mRNA differs among hyperplastic prostate samples; however, the prostatic expression of  $\alpha_{1D}$ -adrenoceptor mRNA is frequently increased in such condition (Nasu et al., 1996; Kojima et al., 2006; 2009a). Some reports have suggested that  $\alpha_{1D}$ -adrenoceptors blockade may improve BPH treatment by inhibiting prostate cell growth *in vitro* and *in vivo* (Kojima et al., 2009a). On the other hand, tamsulosin, one of the most widely used drug for BPH treatment, is not as effective in this model (Kojima et al., 2009a). However, it should be mentioned that detection of the  $\alpha_1$ -adrenoceptor protein is controversial due to the lack of highly selective antibodies validated under stringent conditions (Pradidarcheep et al., 2009; Böhmer et al., 2014). The discrepancies in the reported mRNA and protein expression in the prostate warrant that caution needs to be exercised until additional data are obtained. Human bladder also expresses  $\alpha_{1D}$ -adrenoceptors (Malloy et al., 1998) and both the expression and function increase due to bladder outlet obstruction, both in rat and man (Hampel et al., 2002; Barendrecht et al., 2009).

In the case of multifactorial diseases such as BPH (Roehrborn, 2008), a multi-target strategy seems more appropriate (Peters, 2013). For the treatment of BPH, the use of antagonists that concomitantly relax the prostate and slow prostate enlargement might be more effective than monotherapy targeting solely the  $\alpha_{1A}$ -adrenoceptors (Hieble, 2011), so that we hypothesized that not only  $\alpha_{1D}$ -adrenoceptors but also 5-HT<sub>1A</sub> receptors could be additional targets. In fact, neuroendocrine cells populate normal and malignant prostate tissue releasing 5-HT (Abrahamsson et al., 1986), and prostate cells, including those from BPH patients, express 5-HT<sub>1A</sub> receptors (Dizeyi et al., 2004).

JPET #227066

Moreover, 5-HT<sub>1A</sub> receptor activation appears to increase prostate cell proliferation, via stimulation of the Akt/MAPK pathway (Hsiung et al., 2005; Dizeyi et al., 2011), and the 5-HT<sub>1A</sub> receptor antagonist NAN190 reduces prostate cell proliferation (Dizeyi et al., 2004). Based on these data, 5-HT<sub>1A</sub> receptors are considered as an attractive target for drug development in such context (Fiorino et al., 2014).

Previously, we showed that the *N*1-(2-methoxyphenyl)-*N*4-piperazine moiety confers affinity for  $\alpha_{1A}$ -,  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors (Chagas-Silva et al., 2014). Here, we investigate the *in vitro* and *in vivo* pharmacological characteristics of three *N*-phenylpiperazine derivatives LDT3, LDT5 and LDT8 (European patent office, application No. 13733873.7-1451; USPTO application No. 14370646). Our results show that LDT3 and LDT5 are very potent multi-target antagonists of both  $\alpha_{1A}$ - and  $\alpha_{1D}$ -adrenoceptors, and also of 5-HT<sub>1A</sub> receptors. Also, these compounds inhibit the increase of rat intraurethral pressure (as a result of prostate contraction) *in vivo* and human hyperplastic prostate cell proliferation *in vitro*. As a conclusion, we elected the multi-target LDT3 and LDT5 as potential lead compounds to reduce LUTS/BPH and BPH progression.

## Methods

### *Patient samples and human cell lines*

Prostate tissue samples were collected from three patients with LUTS secondary to BPH during transurethral resection, in accordance with the Declaration of Helsinki (De Souza et al., 2011). Informed consent was obtained from donors (Ethics Committee of UFRJ, CAAE-0029.0.197.000-05; 2009). The androgen-independent prostate cancer cell line DU-145 (human) was obtained from the Rio de Janeiro Cell Bank (UFRJ).

JPET #227066

### ***Animals***

All experiments were conducted in compliance with the Guide for the Care and Use of Laboratory Animals and with institutional ethical standards established by the Ethics Committee of the Federal University of Rio de Janeiro (CEUA), under the license DFBC-ICB-011 (2008). Animals were kept under a 12/12 h light/dark cycle, with water and food *ad libitum*, and in agreement with the guidelines of the National Council on Experimental Animal Control (CONCEA, Brazil) and the Committee of Care and Use of Laboratory Animals (National Research Council, United States). Male Wistar rats (250-300 g; 2-3 months) were used in this study. For brain and liver removal, rats were anesthetized with ether and killed by decapitation.

### ***Test compounds***

The *N*-phenylpiperazine derivatives LDT3, LDT5 and LDT8 (Table 1) were synthesized by LADETER (Universidade Católica de Brasília, Brazil), and were available in the monohydrochloride form, as previously described for other *N*-phenylpiperazine derivatives (Romeiro et al., 2011). IR-FT spectra (Supplemental Figure 1) were recorded on a Spectrum BX spectrometer (Perkin Elmer, Waltham, USA), <sup>1</sup>H-NMR (300 and 500 MHz, CDCl<sub>3</sub>) (Supplemental Figure 2), and <sup>13</sup>C-NMR (75 and 125 MHz, CDCl<sub>3</sub>) spectra were recorded on plus Varian (7.05 T) and Bruker Avance DRX500 and DRX300 spectrometers, and the mass spectra were recorded on a Shimadzu LCMS IT-TOF spectrometer. The spectrometric analysis revealed the presence of only one compound in each sample.

JPET #227066

### ***Drugs and radioligands***

Prazosin hydrochloride, pargyline hydrochloride, 5-hydroxytryptamine hydrochloride (5-HT), acetylcholine chloride, (R)-(-)-phenylephrine hydrochloride, L-adrenaline (+)bitartrate, ( $\pm$ )-propranolol hydrochloride, 4-fluoro-N-(2-[4-(2-methoxyphenyl)1-piperazinyl]ethyl)-N-(2-pyridinyl)benzamide dihydrochloride (*p*-MPPF), 8-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione dihydrochloride (BMY7378), 8-hydroxy-2-(dipropylamino)tetralin hydrobromide (8-OH-DPAT), 2-methoxy idazoxan (RX821002), 3-quinuclidinyl benzilate (QNB), tamsulosin hydrochloride, ketanserin tartrate, polyethyleneimine, atropine sulphate and guanosine-5'-triphosphate (GTP) were purchased from Sigma-Aldrich (St. Louis, USA). [ $^3\text{H}$ ]-prazosin (85 Ci/mmol), [ $^3\text{H}$ ]-ketanserin (60 Ci/mmol), [ $^3\text{H}$ ]-8-OH-DPAT (187 Ci/mmol) and [ $^3\text{H}$ ]*p*-MPPF (74.2 Ci/mmol) were obtained from PerkinElmer (Waltham, USA). [ $^3\text{H}$ ]RX821002 (60 Ci/mmol) and [ $^3\text{H}$ ]-QNB (250 Ci/mmol) were obtained from Amersham (UK).

### ***Isometric contraction assays***

Rat prostate and thoracic aorta were removed, cleaned and cut into 10 mm strips (prostate) or 3 mm rings (aorta). Isometric contraction assays were performed as described previously (Chagas-Silva et al., 2014). Samples were placed in an organ bath containing a physiological solution ([prostate, mM]: NaCl 138, KCl 5.7, CaCl<sub>2</sub> 1.8, NaH<sub>2</sub>PO<sub>4</sub> 0.36, NaHCO<sub>3</sub> 15 and glucose 5.5; [aorta, mM]: NaCl 122, KCl 5, NaHCO<sub>3</sub> 15, glucose 11.5, MgCl<sub>2</sub> 1.25, CaCl<sub>2</sub> 1.25 and KH<sub>2</sub>PO<sub>4</sub> 1.25) (95% O<sub>2</sub> and 5% CO<sub>2</sub>, 37°C). Prostate and denuded aorta segments were preloaded (60 min) with 10 or 20 mN, respectively, and washed twice. Tissues were contracted with 1  $\mu\text{M}$  phenylephrine (aorta) or 60 mM KCl depolarizing solution (prostate). After a 60-min recovery period,



JPET #227066

aorta and prostate samples were contracted with cumulative concentrations of phenylephrine ( $10^{-9}$  –  $10^{-3}$  M) in the presence of 1  $\mu$ M propranolol, before and after incubation for 60 min with the test compounds (10 or 50 nM), BMY7378 or tamsulosin (10 nM). The developed force was recorded using an FT-03 grass force transducer (Warwick, RI, USA) connected to a data acquisition system (PowerLab, ADInstruments, Bella Vista, Australia). Data were analyzed by nonlinear regression (GraphPad Prism 5.0, GraphPad Software, San Diego California USA), and the maximal contraction obtained in each control curve (before treatment) was defined as the top. The phenylephrine concentration that produced 50% of the maximal contraction ( $EC_{50}$ ) was estimated before and after treatment with the antagonists. An  $EC_{50}$  ratio (CR) was calculated for each drug concentration by dividing the  $EC_{50}$  value after treatment by the control value (before treatment). Drug affinity ( $K_B$ ) was estimated using the Schild equation:  $\log (CR-1) = \log [B] - \log K_B$  (Kenakin, 1993), where B is the antagonist.

### ***Intracellular $Ca^{2+}$ measurement***

The effect of LDTs on human  $\alpha_1$ -adrenoceptor subtypes was determined by measuring intracellular  $Ca^{2+}$  in rat-1 fibroblasts stably expressing  $\alpha_{1A}$ -,  $\alpha_{1B}$ - or  $\alpha_{1D}$ -adrenoceptors (Vázquez-Prado et al., 1997). These cells were cultured in high-glucose Dulbecco's- modified Eagle's medium with L-glutamine supplemented with 10% fetal bovine serum, 300  $\mu$ g/ml neomycin analogue G418 sulfate, 100  $\mu$ g/ml streptomycin, 100 units/ml penicillin and 0.25  $\mu$ g/ml amphotericin B, at 37°C and under a 5%  $CO_2$  atmosphere.

Cells were loaded with 2.5  $\mu$ M fura-2/AM for 60 min at 37°C, in 20 mM HEPES (pH 7.4) containing 120 mM NaCl, 1.2 mM  $KH_2PO_4$ , 1.2 mM  $MgSO_4$ , 4.75 mM KCl,

JPET #227066

10 mM glucose, 1.2 mM CaCl<sub>2</sub>, 0.05% bovine serum albumin, pH 7.4. Then, cells were detached by gentle trypsinization, washed to remove unincorporated dye, and incubated (10<sup>6</sup> cells/condition) with vehicle, LDTs (10<sup>-9</sup> – 10<sup>-5</sup> M), BMY7378 (10<sup>-9</sup> – 10<sup>-6</sup> M) or tamsulosin (10<sup>-10</sup> – 10<sup>-7</sup> M) for 100 sec, before stimulation with 100 μM phenylephrine. Fluorophore excitation was performed at 340 and 380 nm and measured at 510 nm emission wavelength, at 0.5-sec intervals, using an Aminco-Bowman Series 2 luminescence spectrometer (Rochester, NY, USA). Peak fluorescence values were used for data analysis, and the intracellular Ca<sup>2+</sup> concentration ([Ca<sup>2+</sup>]<sub>i</sub>) was calculated as described previously (Grynkiewicz et al., 1985). Data were analyzed by computerized nonlinear regression of untransformed data (GraphPad Prism 5.0, GraphPad Software, San Diego California USA), to estimate the half-maximum inhibitory concentration (IC<sub>50</sub>) of test compounds based on individual curves obtained from *n* experiments.

### ***Intraurethral and blood pressure assays***

Male Wistar rats were cannulated as described previously (Chagas-Silva et al., 2014). For these assays, each animal was used only once, and all drugs were diluted in isotonic saline. Blood and intraurethral pressure (in mmHg) were monitored continuously using a fluid filled pressure transducer (PowerLab, ADInstruments, Australia).

Rats were anesthetized with sodium pentobarbital (60 mg.kg<sup>-1</sup> body weight, i.p.), and body temperature was kept constant at 37°C. The jugular vein was cannulated with polyethylene cannulae containing a heparinized saline solution (50 U/ml). Anesthesia was complemented with sodium pentobarbital before treatments. The pressure transducer was placed into the right carotid artery. After blood pressure stabilization

JPET #227066

(30 min), 0.1  $\mu\text{g}\cdot\text{kg}^{-1}$  of LDT3, 0.1 – 100  $\mu\text{g}\cdot\text{kg}^{-1}$  of LDT5, or 100  $\mu\text{l}$  vehicle (saline) were injected i.v., *in bolus*. Data were analysed by LabChart software. Mean arterial (blood) pressure was calculated by arithmetic mean of the diastolic and systolic pressures in the respective cycles and changes were expressed as percentage of the alteration of the baseline (resting) values ( $130.2 \pm 2.2$  mmHg,  $n = 20$ ).

For intraurethral pressure (IUP) determination, the prostate and bladder were exposed through a midline incision in the lower abdomen. The pressure catheter was placed into the prostatic urethra through the bladder and fixed at the vesical-urethral junction with a suture. The distal side of the urethra was also closed with a suture. The IUP was equilibrated at 20 mmHg by injecting a small volume of saline. After approximately 30 min, IUP was increased by an i.v. administration of 1-100  $\mu\text{g}\cdot\text{kg}^{-1}$  phenylephrine every 10 min. Alternatively, a single dose of 30  $\mu\text{g}\cdot\text{kg}^{-1}$  phenylephrine was injected 10 min after the administration of 0.1  $\mu\text{g}\cdot\text{kg}^{-1}$  LDT3 and LDT5 as a first evaluation of the pharmacological effect. Then, full dose-response curves were constructed using LDT3 or LDT5 (0.01 – 3  $\mu\text{g}\cdot\text{kg}^{-1}$ , i.v.) or tamsulosin (0.001 – 0.1  $\mu\text{g}\cdot\text{kg}^{-1}$  i.v.). Data were analyzed by nonlinear regression (GraphPad Prism 5.0, GraphPad Software, San Diego California USA) to determine the half-maximum effective dose ( $\text{ED}_{50}$ ).

### ***Binding assays with native receptors***

Rat brains were removed to obtain the hippocampus (5-HT<sub>1A</sub> receptor) and cortex (5-HT<sub>2A</sub>,  $\alpha_2$ -adrenoceptor and muscarinic receptors; Supplemental Methods) and stored in liquid nitrogen. Hippocampal and cortical membrane samples were prepared as previously described (Neves et al., 2010). After incubation, binding samples were diluted (3 times in 4 ml) in ice-cold 5 mM Tris-HCl buffer (pH 7.4) and subjected to

JPET #227066

rapid filtration under vacuum using glass fiber filters (GMF 3, Filtrak, Germany) pre-soaked in 0.5% polyethyleneimine ( $[^3\text{H}]$ -ketanserin,  $[^3\text{H}]$ -8-OH-DPAT and  $[^3\text{H}]$ RX821002 assays) or binding buffer ( $[^3\text{H}]$ -*p*-MPPF and  $[^3\text{H}]$ -prazosin assays). Radioactivity was determined using a Tri-Carb B2810 TR liquid scintillation counter (PerkinElmer, Waltham, USA). All assays were performed in triplicate. In all cases, the assay volume was 0.5 ml and the radioligand depletion at the end of the experiments was less than 15% with the exception of the assays with  $[^3\text{H}]$ -prazosin in the rat liver preparation (35%). Ideally, radioligand depletion should be seized to less than 10% (Hulme and Trevethick, 2010), so that we have to consider here a possible technical limitation on the precision of the affinity estimation, at least for the data with  $[^3\text{H}]$ -prazosin in the rat liver preparation, the assay used for labeling the off-target  $\alpha_{1B}$  adrenoceptors. Nevertheless, the  $pK_d$  value of  $[^3\text{H}]$ -prazosin for  $\alpha_{1B}$ -adrenoceptors was 9.29 (0.51 nM), which was close to the value previously reported ( $pK_d$   $9.98 \pm 0.27$ ; Ohmura and Muramatsu, 1995).

For 5-HT<sub>1A</sub> receptor assays, 50  $\mu\text{g}$  membrane protein were incubated with LTDs ( $10^{-12}$  –  $10^{-6}$  M) in binding buffer containing 1 nM  $[^3\text{H}]$ -8-OH-DPAT (agonist), 1 mM CaCl<sub>2</sub>, 1 mM MnCl<sub>2</sub> and 10  $\mu\text{M}$  pargyline (for 15 min at 37°C) or 0.5 nM  $[^3\text{H}]$ -*p*-MPPF (antagonist) and 1 mM GTP (for 45 min at 37°C). Nonspecific binding was determined in the presence of 10  $\mu\text{M}$  5-HT. The intrinsic activity of LTDs at 5-HT<sub>1A</sub> receptors was determined as described by Assié et al. (1999), using the dissociation constants ( $K_i$ ) of the LTDs obtained for agonist ( $[^3\text{H}]$ -8-OH-DPAT) binding ( $K_{i \text{ High}}$ ) and for antagonist ( $[^3\text{H}]$ -*p*-MPPF) binding in the presence of a high concentration of GTP ( $K_{i \text{ Low}}$ ).  $K_{i \text{ Low}}/K_{i \text{ High}}$  values higher than 1.0 indicate agonism, values close to 1.0 suggest antagonism and values lower than 1.0 indicate inverse agonism (Noël et al., 2014).

JPET #227066

Rat livers ( $\alpha_{1B}$ -adrenoceptors) were minced in ice-cold 5 mM Tris (pH 7.4) containing 0.25 M sucrose and 1 mM EGTA, and then homogenized twice in 50 mM Tris HCl (pH 7.4) containing 100 mM NaCl and 2 mM EDTA (1:6, w:v), using an Ultra Turrax homogenizer. Liver homogenates were filtered through four layers of gauze and centrifuged at  $5,000 \times g_{max}$ , for 20 min at 4°C. Supernatants were ultracentrifuged at  $100,000 \times g_{max}$ , for 60 min at 4°C, and final pellets were diluted in 5 mM Tris-HCl (pH 7.4) containing 0.25 M sucrose (Michel et al., 1994). The protein content was determined according to Lowry et al. (1951), using bovine serum albumin as a standard. Then, 150  $\mu$ g liver membrane protein were incubated with test compounds ( $10^{-9}$  –  $10^{-6}$  M) and 0.1 nM [ $^3$ H]-prazosin, in binding buffer containing 1 mM EDTA, for 45 min at 30°C. Nonspecific binding was defined in the presence of 1  $\mu$ M prazosin. Alternatively, saturation assays were performed using prazosin at concentrations ranging from 0.0001 to 0.1  $\mu$ M (Chagas-Silva et al., 2014).

The binding assays for the  $\alpha_2$ -adrenoceptors, 5-HT<sub>2A</sub> and muscarinic receptors are described in the supplementary material.

### ***Analysis of binding assays***

Data were analyzed by computerized nonlinear regression of untransformed data (GraphPad Prism 5.0, GraphPad Software, San Diego California USA), to estimate the half-maximum inhibitory concentration (IC<sub>50</sub>) of test compounds or radioligand  $K_d$  values. Dissociation constants ( $K_i$ ) were calculated using the Cheng and Prusoff equation (Cheng and Prusoff, 1973).

The  $K_d$  of [ $^3$ H]-prazosin for  $\alpha_{1B}$ -adrenoceptors was 0.51 nM, the  $K_d$  of [ $^3$ H]RX821002 for  $\alpha_{2A}$ -adrenoceptors was 2.05 nM and the  $K_d$  of [ $^3$ H]-*p*-MPPF for 5-HT<sub>1A</sub> receptors was 0.86 nM (Chagas-Silva et al., 2014). The  $K_d$  values of [ $^3$ H]-8-OH-

JPET #227066

DPAT for 5-HT<sub>1A</sub> receptors (0.7 nM) and of [<sup>3</sup>H]-ketanserin for 5-HT<sub>2A</sub> receptors (1.7 nM) were previously estimated in our experimental conditions (Neves et al., 2010).

### ***Cell growth assays***

Human DU145 prostate cancer cells (75<sup>th</sup> - 77<sup>th</sup> passage) and prostate cells from BPH patients (9<sup>th</sup> - 11<sup>th</sup> passage; De Souza et al., 2011) were cultured in RPMI 1640 or DMEM, respectively, supplemented with 10% fetal bovine serum, 1% sodium pyruvate and 1% penicillin/streptomycin (37°C, 5% CO<sub>2</sub>), until confluence. For cell growth assays, 5 x 10<sup>3</sup> or 3 x 10<sup>3</sup> cells/well (for DU145 and BPH, respectively) were seeded in 96-well plates and cultured in serum-free medium for 24h, and then incubated for 48h in medium containing 2.5% fetal bovine serum and 1 μM 5-HT or 3 μM phenylephrine, in the absence or presence of LDTs, BMY7378 or *p*-MPPF (fresh medium with drugs was added at 24h). Cell growth was evaluated by counting of viable cells using Trypan blue as an exclusion dye or by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Data were expressed as the percentage of the control condition (vehicle).

### ***Statistical analysis***

Otherwise indicated, data are expressed as means and SD. The significance of the differences among two or more conditions was determined by Student's *t* test or one-way analysis of variance (ANOVA), respectively. ANOVA was followed by *post hoc* Dunnett's or Newman-Keuls test. The F values calculated with the software GraphPad Prism 5.0 for the ANOVA prior to post-hoc tests are indicated in the legend of the tables and figures. Differences were considered statistically significant if *P* < 0.05.

JPET #227066

## Results

### *LDT3, LTD5 and LDT8 have high affinity for native $\alpha_{1A}$ - and $\alpha_{1D}$ -adrenoceptors, but not for off-target receptors.*

In assays using rat prostate, where the subtype  $\alpha_{1A}$ -adrenoceptor is the most important for contraction (Hiraoka et al., 1999), our results indicate that LDT3, LDT5 and LDT8 have high affinity for  $\alpha_{1A}$ -adrenoceptors, with  $K_B$  values ranging from 0.17 to 2.62 nM (Fig. 1A, Table 2), close to those for the anti-BPH drug tamsulosin and slightly smaller than the previous derivative LDT66 (Table 2).

In rat aorta, where the main  $\alpha_1$ -adrenoceptors responsible for contraction belong to the  $\alpha_{1D}$ -subtype (Hussain and Marshall, 1997), treatment with *N*-phenylpiperazine derivatives also induced a shift of the phenylephrine concentration-response curves to the right, suggesting a surmountable antagonism (Fig. 1B). All LDTs showed high affinity for  $\alpha_{1D}$ -adrenoceptors, with  $K_B$  values in the low nanomolar range (Table 2), and the affinities of LDT5 and LDT8 for these receptors ( $K_B = 0.59$  and  $0.18$  nM, respectively) were significantly higher than that of the selective antagonist BMY7378 ( $K_B = 2.95$  nM; Table 2).

Analysis of the monophasic binding competition curves obtained with LDTs indicates that LDTs have lower affinity for  $\alpha_{1B}$ -adrenoceptors than prazosin (Fig.1C), with mean  $K_i$  values ranging from 7 to 80 nM, compared with  $K_i = 0.3$  nM for prazosin ( $n = 3$ ,  $P < 0.05$ ). Moreover, test compounds  $K_i$  values were also higher than their  $K_B$  values for  $\alpha_{1D}$ - and  $\alpha_{1A}$ -adrenoceptors ( $P < 0.05$ ). Indeed, LDT3 ( $K_i = 80$  nM,  $n = 4$ ), LDT5 ( $K_i = 10$  nM,  $n = 5$ ) and LDT8 ( $K_i = 7$  nM,  $n = 5$ ) had 17 to 41 fold less affinity for the  $\alpha_{1B}$ - than for the  $\alpha_{1D}$ -adrenoceptors (Table 2). In this experimental condition,

JPET #227066

tamsulosin showed a  $K_i$  value of 5.9 nM for  $\alpha_{1B}$ -adrenoceptors (Chagas-Silva et al., 2014), in agreement with previous reports (Williams et al., 1999; Pulito et al., 2000).

We also evaluated the affinity of LDT3, LDT5 and LDT8 for the BPH off-target  $\alpha_2$ -adrenoceptors and muscarinic receptors, using binding competition assays. LDTs showed  $K_i$  values in the micromolar range (0.2 – 108  $\mu$ M), indicating a very low affinity for  $\alpha_2$ -adrenoceptors and muscarinic receptors (Supplemental Table 1).

***LDT3 and LDT5 are high affinity antagonists of 5-HT<sub>1A</sub> receptors, with low affinity for the off-target 5-HT<sub>2A</sub>.***

Competition binding experiments revealed that all test compounds had high affinity for 5-HT<sub>1A</sub> receptors, with  $K_i$  values in the low nanomolar range for LDT3 and LDT5, and significantly lower for LDT8 ( $K_i = 9$  pM,  $P < 0.05$ ; Table 3). As the selectivity between 5-HT receptor sub-types is therapeutically relevant, we also measured the affinity of LDTs for the off-target 5-HT<sub>2A</sub> receptor. All three LDTs had lower affinity for 5-HT<sub>2A</sub> receptors ( $K_i = 70$ -389 nM) than for 5-HT<sub>1A</sub> receptors, and 5-HT<sub>2A</sub>/5-HT<sub>1A</sub> ratios suggested high selectivity for 5-HT<sub>1A</sub> (60 to 44,000 fold; Supplemental Table 2).

We also determined the intrinsic activity of our compounds towards 5-HT<sub>1A</sub> receptors. For this purpose we used the  $K_i$  ratio method, a functional binding assay that we recently described and compared to two other methods (GTP-shift and [<sup>35</sup>S]-GTP $\gamma$ S binding assay), for estimation of the intrinsic activity at the 5-HT<sub>1A</sub> receptor (Noël et al., 2014). Using the  $K_i$  ratio method, the full agonist 5-HT showed a  $K_i$  ratio of 76.8. The results in Table 3 suggest that LDT3 and LDT5 are 5-HT<sub>1A</sub> receptor antagonists ( $K_i$  ratio close to unity), while LDT8 had a  $K_i$  ratio value compatible with a partial agonist. Since antagonism at the 5-HT<sub>1A</sub> receptor is supposed to be a pre-requisite for efficacy of



JPET #227066

the type of multi-target BPH lead compound we aimed to develop, we interrupted the pharmacological characterization of LDT8 at this point.

***LDT3 and LDT5 inhibit the proliferation of prostate cells from BPH patients.***

LDT3 and LDT5 behaved as high-affinity antagonists of rat  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors (Table 2 and 3); thus, we decided to verify whether these compounds had anti-proliferative activity against prostate cells from BPH patients. To induce prostate cell proliferation *in vitro*, we used 3  $\mu$ M of either phenylephrine or 5-HT, and the antagonists BMY7378 and *p*-MPPF (50 nM) were used as positive controls for  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub>-receptor inhibition, respectively. The LDTs concentration used (50 nM) corresponded to ~30-50 fold the estimated *in vitro* affinity of these compounds for  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors. Counts of viable cells grown for 48h in the presence of LTDs showed that both LDT3 and LDT5 inhibited BPH cell growth induced by phenylephrine and 5-HT, similarly to that observed for BMY7378 (Fig. 2A) and *p*-MPPF (Fig. 2B). We did not observe clear cytotoxic effects when LTDs were used alone (not shown). Note that tamsulosin produced only partial inhibition of phenylephrine-induced growth at 5 nM (Fig. 2A), a concentration ~50-fold higher than the *K<sub>i</sub>* we reported for the  $\alpha_{1D}$ -adrenoceptors (Table 2; Chagas-Silva et al., 2014). Similar effects of LTDs on BPH cells were obtained using the MTT assay ( $P < 0.001$ ; Supplemental Figure 3).

In agreement with the results of cell proliferation assays using non-transformed BPH patient cells (Fig. 2), LDT3 and LDT5 also inhibited the 5-HT-stimulated growth of the prostate cancer cell line DU-145 (Supplemental Figure 4). Interestingly, LDT8 stimulated DU-145 cell growth (Supplemental Figure 4), which is compatible with the partial 5-HT<sub>1A</sub> agonist activity detected for this compound in binding assays (Table 3).

JPET #227066

***LDT3 and LDT5 decrease phenylephrine-induced calcium elevation in cells overexpressing human  $\alpha_{1A}$ - and  $\alpha_{1D}$ -adrenoceptors.***

To confirm the antagonistic properties of LDT3 and LDT5 towards different human  $\alpha_1$ -adrenoceptor subtypes, we used a functional assay based on intracellular  $\text{Ca}^{2+}$  ( $[\text{Ca}^{2+}]_i$ ) elevation in Rat-1 cells overexpressing human  $\alpha_{1A}$ -,  $\alpha_{1D}$ - or  $\alpha_{1B}$ -adrenoceptors (Vázquez-Prado et al., 1997). In Rat-1 cells expressing  $\alpha_{1D}$ -adrenoceptors, stimulation with 100  $\mu\text{M}$  phenylephrine (PHE) typically induced a pronounced and transient increase in  $[\text{Ca}^{2+}]_i$  levels (Fig. 3A). In contrast, we observed a considerably less pronounced increase in  $[\text{Ca}^{2+}]_i$  after phenylephrine stimulation in cells incubated with LDT3 (Fig. 3B and C) or LDT5. For these  $\alpha_{1D}$ -adrenoceptors, the mean  $p\text{IC}_{50}$  (and SD) values of LDT3 and LDT5 were  $8.5 \pm 0.67$  ( $n = 6$ ) and  $8.38 \pm 0.06$  ( $n = 4$ ), respectively (Supplemental Figure 5). The  $p\text{IC}_{50}$  value of BMY7378 was  $8.53 \pm 0.08$  ( $n = 3$ ). LDT3 and LDT5 also had a high potency at  $\alpha_{1A}$ -adrenoceptors, with  $p\text{IC}_{50}$  values of  $7.53 \pm 0.37$  and  $7.16 \pm 0.51$ , respectively ( $n = 3$ ), which were smaller than for tamsulosin ( $8.36 \pm 0.33$ ,  $n = 3$ ,  $F_{2,6} = 6.718$ ,  $P = 0.0294$ .  $P < 0.05$  one way ANOVA followed by Newman-Keuls test). On the other hand, LDT3 and LDT5 had considerably lower affinity for  $\alpha_{1B}$ -adrenoceptors, with  $p\text{IC}_{50}$  values for inhibition of  $[\text{Ca}^{2+}]_i$  elevation of  $6.10 \pm 0.29$  and  $5.88 \pm 0.34$  ( $n = 3$ ), respectively ( $P < 0.05$  versus  $\alpha_{1A}$ - and  $P < 0.001$  versus  $\alpha_{1D}$ -adrenoceptors). In this assay, the  $p\text{IC}_{50}$  value for tamsulosin was  $8.8 \pm 0.57$  ( $n = 4$ ). The overall ranking of potency of LDT3 and LDT5 at human  $\alpha_1$ -adrenoceptors subtypes was  $\alpha_{1D} > \alpha_{1A} > \alpha_{1B}$  (LDT3:  $F_{2,9} = 19.41$ ,  $P = 0.0005$ ; LDT5:  $F_{2,6} = 37.08$ ,  $P = 0.0004$ .  $P < 0.01$  one way ANOVA followed by Newman-Keuls test).

JPET #227066

***LDT3 and LDT5 prevent phenylephrine-induced increase in intraurethral pressure, and do not affect basal blood pressure.***

As prostate contraction increases intraurethral pressure (Akiyama et al., 1999), we investigated the effect of LDTs on rat intraurethral pressure (IUP) *in vivo*. Phenylephrine increased IUP in a dose-dependent manner, with an ED<sub>50</sub> value of 7.5 μg.kg<sup>-1</sup> (Fig. 4A). Pre-treatment with either LDT3 or LDT5 (0.1 μg.kg<sup>-1</sup>, i.v.) prevented the phenylephrine-induced increase in IUP (30 μg.kg<sup>-1</sup>), and LDT5 was more effective than LDT3 (Fig.4B). In higher doses both compounds fully blocked the phenylephrine effect. The mean ED<sub>50</sub> values of LDT3 and LDT5 (Fig. 4C), 0.15 and 0.09 μg.kg<sup>-1</sup>, respectively, were higher than the ED<sub>50</sub> value of tamsulosin (0.007 μg.kg<sup>-1</sup>).

Considering that hypotension is a classical adverse effect of α<sub>1</sub>-antagonists, we evaluated the effect of LDT3 and LDT5 on rat basal blood pressure. We observed a small reduction in basal blood pressure after treatment with 0.1 μg.kg<sup>-1</sup> LDT3 and LDT5 (mean and SD: -2.92 ± 2.6 and -2.13 ± 1.49%, respectively; n = 6), but this effect was not statistically different from that observed when saline was used as control (0.046 ± 6.5%; n = 5; P = 0.46). In addition, we further explored the effect of higher doses of LDT5, and only the dose of 100 μg.kg<sup>-1</sup>, i.v. reduced significantly the basal blood pressure (Fig. 4D).

JPET #227066

## Discussion

Randomized controlled clinical trials have shown that blockage of prostatic  $\alpha_1$ -adrenoceptor is the most effective pharmacological management for relieving LUTS/BPH. For instance, both short- and long-term studies have shown that this pharmacological class improves the symptoms and the urinary flow rate (Lepor et al., 1996; Kirby et al., 2003; McConnell et al., 2003; Chapple, 2005). However,  $\alpha_{1A}$ -adrenoceptor or uroselective  $\alpha_1$ -adrenoceptor antagonists show better tolerability (Chapple, 2005; McVary et al., 2011; Oelke et al., 2013). Nevertheless, some patients may be unresponsive to  $\alpha_{1A}$ -adrenoceptor blockade (Kaplan, 2006), which limits the efficacy of  $\alpha_{1A}$ -adrenoceptor antagonists; in such cases the risk of acute urinary retention is not reduced (McVary et al., 2011). The improvement of LUTS/BPH mediated by the association of 5- $\alpha$  reductase inhibitors with  $\alpha_1$ -adrenoceptor blockers as compared to monotherapy with  $\alpha_1$ -adrenoceptor blockers is only clearly observed after long-term therapy, while some adverse effects of 5- $\alpha$  reductase inhibitors may reduce patient compliance to treatment (McConnell et al., 2003; Chapple, 2005; Nickel, 2006; Tarle et al., 2009; Oelke et al., 2013). Here, we show that the *N*-phenylpiperazine derivatives LDT3 and LDT5 inhibit rat prostate muscle contraction *in vivo* and human hyperplastic prostate cell growth *in vitro*.

Some diseases, including BPH, are multifactorial (Roehrborn, 2008), most likely requiring multi-target strategies to improve therapeutic efficacy (Morphy et al., 2004; Lu et al., 2012). For the clinical management of BPH, we hypothesized that targeting of  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors, in addition to  $\alpha_{1A}$ -adrenoceptor antagonism, could be particularly interesting because both receptors stimulate prostate cell growth (Dizeyi et al., 2004; Kojima et al., 2009a),  $\alpha_{1D}$ -adrenoceptors mRNA expression is

JPET #227066

increased in BPH (Kojima et al., 2009a) and non-prostatic  $\alpha_{1D}$ -adrenoceptors may contribute to bladder overactivity (Malloy et al., 1998; Kurizaki et al., 2001; Michel, 2010).

The  $\alpha_{1A}$ -adrenoceptor mediates human (Forray et al., 1994) and rat (Hiraoka et al., 1999) prostatic contraction (Michel and Vrydag, 2006). LDT3, LDT5 and LDT8 had high affinity for  $\alpha_{1A}$ -adrenoceptors in functional assays (Table 2). The affinities of LDT5 and LDT8 for rat  $\alpha_{1A}$ -adrenoceptors were similar to that of the clinically used anti-BPH agent tamsulosin (Table 2; Noble et al., 1997), and higher than the previous derivative LDT66.

Aside from their high affinity for rat and human  $\alpha_{1A}$ - and  $\alpha_{1D}$ -adrenoceptors, LDT3 and LDT5 also have low affinity for the off-target  $\alpha_{1B}$  subtype, in both species.  $\alpha_1$ -Adrenoceptor blockers are considered similar in efficacy to reduce LUTS/BPH but they differ in tolerability (Michel, 2010; Kim et al., 2014). For instance, silodosin may be adequate to BPH patients receiving antihypertensive treatment (as this drug has little impact on blood pressure), while alfuzosin may be suitable for sexually active patients (as silodosin has the highest risk of ejaculatory dysfunction) (Chapple, 2005; Kim et al., 2014). Since human vascular expression of  $\alpha_{1B}$ -adrenoceptors increases in aging (Rudner et al., 1999) the low affinity of LDT3 and LDT5 for this receptor subtype may also reduce the risk of hypotension, a classical adverse effect of therapy with  $\alpha_1$ -adrenoceptor antagonists (Jelski and Speakman, 2012). Moreover, some data suggest that tamsulosin could be more prone to induce high grade intraoperative floppy iris syndrome (McVary et al., 2011; Chang et al., 2014).

Despite the fact that rat prostate does not surround urethra it contributes to the increase of the intraurethral pressure (Akiyama et al., 1999). Data from *in vivo* assays indicated clearly that LDT3 and LDT5 blocked the increase in rat intraurethral pressure

JPET #227066

induced by phenylephrine (Fig. 4B), and LDT5 has an  $ED_{50}$  value of  $0.09 \mu\text{g}\cdot\text{kg}^{-1}$  (Fig. 4C). In the same model, a similar dose of the previous derivative LDT66 ( $0.1 \mu\text{g}\cdot\text{kg}^{-1}$  iv) was around 20% less effective than LDT5 (*data not shown*). Therefore, our results suggest that LDT3 and LDT5 are capable to relax rat prostate. If translated to human prostate, we hypothesize that they could inhibit the dynamic component of BPH. Furthermore, we also showed that a similar dose of LDT3 and LDT5 ( $0.1 \mu\text{g}\cdot\text{kg}^{-1}$ ) did not affect rat basal blood pressure, which suggests uroselectivity at least for LDT5. Based on our results it is possible that LDT5, in the doses used to reduce LUTS, would be neutral in relation to blood pressure.

The role of G protein-coupled receptors in cell growth has been investigated (revised in Liebmann, 2011). Keffel and colleagues (2000) showed in CHO cells that the stimulation of transfected human  $\alpha_{1D}$ -adrenoceptor increases cell growth and ERK signaling. Moreover, it was shown that receptor stimulation induces proliferation of smooth muscle cells and fibroblasts from the adventitia of rat aorta, and the mechanism involved epidermal growth factor receptor transactivation (Zhang et al., 2004). *In vivo*, chronic stimulation of  $\alpha_1$ -adrenoceptors induces rat prostatic hyperplasia involving transforming growth factor (TGF)- $\beta$  signaling (Kim et al., 2009). Actually, TGF- $\beta$  signaling has been considered as one of the mechanisms that contribute to human prostate enlargement (Descazeaud et al., 2011).

$\alpha_{1D}$ -Adrenoceptor mRNA have been shown in human hyperplastic prostate samples (Nasu et al., 1996; Kojima et al., 2006; 2009a; Morelli et al., 2014). Naftopidil, which has 3 and 17 times higher affinity for human  $\alpha_{1D}$ - than for  $\alpha_{1A}$ - and  $\alpha_{1B}$ -adrenoceptors, respectively (Takei et al., 1999), reduces prostate cell growth by arresting cell-cycle at G1 phase (Kojima et al., 2009a,b). However the presence of

JPET #227066

prostatic  $\alpha_{1D}$ -adrenoceptor at protein level is still controversial which warrants further investigation (Michel and Vrydag, 2006; Kojima et al., 2009b).

LDT3 and LDT5 inhibited the phenylephrine-induced growth of prostate cells from BPH patients (Fig. 2, Supplemental Figure 3), and of DU-145 prostate cancer cells in a way qualitatively similar to BMY7378, which suggests the role of  $\alpha_{1D}$ -adrenoceptors (Supplemental Figure 4). In our model, although LDT66 blocked the phenylephrine effect (DU-145) ( $P < 0.01$ ), it also caused a slight proliferative effect when used alone (Chagas-Silva et al., 2014). Other  $\alpha_1$ -adrenoceptor antagonists with a quinazoline moiety also inhibit prostate cell growth *in vitro*; however, this effect is independent of  $\alpha_1$ -adrenoceptor and involves anoikis in prostate cells mediated by death receptors (revised in Kyrianiou et al., 2009). Therefore, the mechanism of action involved in the antigrowth effect of the present *N*-phenylpiperazine derivatives, LDT3 and LDT5, depends on the blockage of the agonist action and differs from the effect of quinazoline drugs.

Another important signaling molecule that stimulates prostate cell growth is 5-HT which is synthesized by neuroendocrine cells (Abrahamsson et al., 1986). 5-HT<sub>1A</sub> receptors stimulate the growth of some cell types such as fibroblasts (Abdel-Baset et al., 1992). Benign and malignant prostate tissues express 5-HT<sub>1A</sub> receptors and mounting evidence suggests that these receptors stimulate prostate cell growth via Akt/MAPK pathway (Abdul et al., 1994; Dizeyi et al., 2004, 2011). Based on binding assays, LDT3 and LDT5 have high affinity for 5-HT<sub>1A</sub> receptors (Table 3). Importantly, LDT3 and LDT5 showed higher affinity for 5-HT<sub>1A</sub> receptors than LDT66 (Chagas-Silva et al., 2014) and naftopidil, another *N*-phenylpiperazine compound ( $K_i = 107$  nM; Borbe et al., 1991).

JPET #227066

LDT3 and LDT5 also inhibited the 5-HT-induced BPH (and DU-145) cell growth in a similar manner to that of the selective 5-HT<sub>1A</sub> receptor antagonist *p*-MPPF (Fig. 2, Supplemental Figure 3), in agreement with the antiproliferative effect of another 5-HT<sub>1A</sub> receptor antagonist (NAN 190) towards prostate cancer PC3 and DU-145 cell lines (Dizeyi et al., 2004). Moreover, while LDT3 and LDT5 blocked completely the agonist effect, LDT66 showed a partial inhibition (Chagas-Silva et al., 2014). On the other hand, LDT8 behaved as a partial agonist of 5-HT<sub>1A</sub> receptors, in both binding and functional (cell growth) assays; thus, we discontinued the pharmacological testing of LDT8 for the purposes of multi-targeted anti-BPH therapy development.

Our data confirm that the *N*1-(2-methoxyphenyl)-*N*4-piperazine scaffold confers affinity for  $\alpha_1$ -adrenoceptors, as well as for 5-HT<sub>1A</sub> receptors (Glennon et al., 1988; Leopoldo et al., 2004; Chagas-Silva et al., 2014), and unveil the multi-target antagonist behavior of the *N*-phenylpiperazine derivatives described here. In addition, LDT5 showed higher affinity for  $\alpha_{1A}$ -,  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors than the previous derivative LDT66, which has a hexil substitution in the *N*<sub>4</sub>-phenylpiperazine moiety (Chagas-Silva et al., 2014), and therefore, this compound showed an improved pharmacological profile at target receptors. This could suggest that the phenethyl auxophoric subunit present in LDT3 and LDT5 (R1, Table 1), and absent in LDT66, is important for the interaction with amino acid residues in the before mentioned receptors.

Also of note, the three LDTs tested here showed low affinity for off-target receptors, including  $\alpha_{1B}$ - and  $\alpha_2$ -adrenoceptors, as well as 5-HT<sub>2A</sub> and muscarinic receptors. Therefore, our data suggest that LDT3 and LDT5 are unlikely to cause the adverse effects associated with inhibition of important off-target receptors. We were also able to discard any interference of LDT3 and LDT5 (1  $\mu$ M) with hERG K<sup>+</sup> channel



JPET #227066

function (not shown), whose blockade can elicit potentially fatal cardiac arrhythmias (Priest et al., 2008) reason why this test is absolutely required for new drug approval by regulatory authorities (Bowes et al., 2012; Peters 2013).

Based on clinical data, current selective  $\alpha_1$ -adrenoceptors antagonists used to manage LUTS/BPH do not shrink prostate (McConnell et al., 2003; Kojima et al., 2009b). Overall, our results showed that LDT3 and LDT5 inhibit human hyperplastic prostate cell growth *in vitro*, while also relaxing prostate muscle, most probably by the multi-target antagonism of  $\alpha_{1A}$ -,  $\alpha_{1D}$ -adrenoceptors and 5-HT<sub>1A</sub> receptors. Therefore, our working hypothesis is that the multi-target mechanism of action of the *N*-phenylpiperazine derivatives LDT3 and LDT5 could modify the course of the disease. If successfully translated to the clinic these two important effects of LDTs could putatively modify the course of the disease by slowing prostate enlargement, and also alleviating LUTS/BPH. Thus, we propose that LDT3 and LDT5 are potential new lead compounds that could be of value for BPH treatment.

JPET #227066

### **Acknowledgments**

The authors thank Orlando R. Moreira (UFRJ, Brazil) for technical assistance. Claudia L. M. Silva, Luiz E. Nasciutti, Luiz A. S. Romeiro and François Noël are senior fellows of CNPq (Brazil).

### **Authorship Contributions**

*Participated in research design:* Silva, Noël, Romeiro, García-Sáinz

*Conducted experiments:* Nascimento-Viana, Carvalho, Alcántara-Hernández, Chagas-Silva

*Contributed new reagents or analytic tools:* Nasciutti, Souza

*Performed data analysis:* Nascimento-Viana, Silva, Noël

*Wrote or contributed to the writing of the manuscript:* Silva, Noël

JPET #227066

## References

- Abdel-Baset H, Bozovic V, Szyf M, Albert PR (1992) Conditional transformation mediated via a pertussis toxin-sensitive receptor signalling pathway. *Mol Endocrinol*. **6**:730-40.
- Abdul M, Anezinis PE, Logothetis CJ, and Hoosein NM (1994) Growth inhibition of human prostatic carcinoma cell lines by serotonin antagonists. *Anticancer Res* **14**: 1215-1220.
- Abrahamsson PA, Wadström LB, Alumets J, Falkmer S, and Grimelius L (1986) Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. *Pathol Res Pract* **181**: 675-683.
- Akiyama K, Hora M, Tatemichi S, Masuda N, Nakamura S, Yamagishi R, Kitazawa M (1999) KMD-3213, an uroselective and long-acting  $\alpha_{1a}$ -adrenoceptor antagonist, tested in a novel rat model. *J Pharmacol Exp Ther* **291**: 81-91.
- Assié MB, Cosi C, and Koek W (1999) Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity. *Eur J Pharmacol* **386**: 97-103.
- Barendrecht MM, Frazier EP, Vrydag W, Alewijnse AE, Peters SLM, Michel MC (2009) The effect of bladder outlet obstruction on  $\alpha_1$ - and  $\beta$ -adrenoceptor expression and function. *Neurourol Urodyn* **28**:349-355.
- Böhmer T, Pfeiffer N, Gericke A (2014) Three commercial antibodies against  $\alpha_1$ -adrenergic receptor subtypes lack specificity in paraffin-embedded sections of murine tissues. *Naunyn Schmiedebergs Arch Pharmacol*. **387**:703-6.
- Borbe OH, Metzner P, and Szelenyi I (1991). 5-HT1A-agonistic properties of naftopidil, a novel antihypertensive drug. *Eur J Pharmacol* **205**: 105-107.
- Bowes J, Brown AJ, Hamon J, Jarolimek W, Sridhar A, Waldron G, Whitebread S (2012) Reducing safety-related drug attrition: the use of in vitro pharmacological

JPET #227066

profiling. *Nat Rev Drug Discov* **11**: 909-922.

Chagas-Silva F, Nascimento-Viana JB, Romeiro LA, Barberato LC, Noël F, and Silva CL (2014) Pharmacological characterization of N1-(2-methoxyphenyl)-N4-hexylpiperazine as a multi-target antagonist of  $\alpha$ 1A/ $\alpha$ 1D-adrenoceptors and 5-HT1A receptors that blocks prostate contraction and cell growth. *Naunyn Schmiedebergs Arch Pharmacol* **387**: 225-234.

Chang DF, Campbell JR, Colin J, Schweitzer C, Study Surgeon Group (2014) Prospective masked comparison of intraoperative floppy iris syndrome severity with tamsulosin versus alfuzosin. *Ophthalmology* **121**:829-834.

Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K<sub>1</sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction. *Biochem Pharmacol* **22**: 3099-3108.

Chapple CR (2005) A comparison of varying  $\alpha$ -blockers and other pharmacotherapy options for lower urinary tract symptoms. *Rev Urol* **7**:S22-S30.

De Souza PA, Palumbo A Jr, Alves LM, de Souza VP, Cabral LM, Fernandes PD, Takiya CM, Menezes FS, Nasciutti LE (2011) Effects of a nanocomposite containing *Orbignya speciosa* lipophilic extract on Benign Prostatic Hyperplasia. *J Ethnopharmacol.* **135**:135-146

Descazeaud A, Weinbreck N, Robert G, Vacherot F, Abbou CC, Labrousse F, Allory Y, Rubin MA, de la Taille A (2011) Transforming growth factor  $\beta$ -receptor II protein expression in benign prostatic hyperplasia is associated with prostate volume and inflammation. *BJU Int.* **108**:E23-8.

Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA (2004) Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. *Prostate* **59**: 328-336.

JPET #227066

- Dizeyi N, Hedlund P, Bjartell A, Tinzl M, Austild-Taskén K, and Abrahamsson PA (2011) Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines. *Urol Oncol* **29**: 436-445.
- Fiorino F, Severino B, Magli E, Ciano A, Caliendo G, Santagada V, Frecentese F, Perissutti E (2014) 5-HT1A receptor: an old target as a new attractive tool in drug discovery from central nervous system to cancer. *J Med Chem* **57**: 4407-4426.
- Forray C, Bard JA, Wetzel JM, Chiu G, Shapiro E, Tang R, Lepor H, Hartig PR, Weinshank RL, Branchek TA, Gluchowski C (1994) The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. *Mol Pharmacol* **45**: 703-708.
- Glennon RA, Naiman NA, Lyon RA, and Titeler M (1988) Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands. *J Med Chem* **31**: 1968-1971.
- Grynkiewicz G, Poenie M, and Tsien RY (1985) A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties. *J Biol Chem* **260**: 3440-3450.
- Hampel C, Dolber PC, Smith MP, Savic SL, Throff JW, Thor KB, Schwinn DA (2002) Modulation of bladder alpha 1-adrenergic receptor subtype expression by bladder outlet obstruction. *J Urol* **167**(3): 1513-1521.
- Hieble JP (2011) Animal models for benign prostatic hyperplasia. *Handbook Exp Pharmacol* **202**: 69 – 79.
- Hiraoka Y, Ohmura T, Oshita M, Watanabe Y, Morikawa K, Nagata O, Kato H, Taniguchi T, Muramatsu I (1999) Binding and functional characterization of  $\alpha_1$ -adrenoceptor subtypes in the rat prostate. *Eur J Pharmacol* **366**: 119-126
- Hsiung SC, Tamir H, Franke TF, and Liu KP (2005) Roles of extracellular signal-

JPET #227066

- Regulated kinase and Akt signaling in coordinating nuclear transcription factor-kappaB-dependent cell survival after serotonin 1A receptor activation. *J Neurochem* **95**: 1653-1666.
- Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. *Br J Pharmacol* **161**:1219-1237
- Hussain MB, Marshall I (1997) Characterization of  $\alpha_1$ -adrenoceptor subtypes mediating contractions to phenylephrine in rat thoracic aorta, mesenteric artery and pulmonary artery. *Br J Pharmacol* **122**: 849-858.
- Jelski J and Speakman M (2012) Alpha adrenoreceptor antagonists—have we reached the optimum balance of safety/efficacy? *Drug Disc Today: Ther Strategies* **9**: e27–e33.
- Kaplan SA (2006) Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. *Rev Urol* **8** Suppl 4: S10-17.
- Kenakin T (1993) Competitive antagonism, in Pharmacologic analysis of drug-receptor interaction (Kenakin, T. ed.) pp 278–322, Raven Press, New York.
- Kim J, Yanagihara Y, Kikugawa T, JiM, Tanji N, Masayoshi Y, Freeman MR (2009) A signaling network in phenylephrine-induced benign prostatic hyperplasia. *Endocrinology* **150**: 3576-3583.
- Kim TN, Nam JK, Lee KS, Kim TH, Park SW, Shin DG, Park HJ, Lee W, Lee ZZ, Chung MK (2014) Reasons for prescription change of  $\alpha_1$ -blockers in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. *Urology* **84**: 427-432.
- Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB; Prospective European Doxazosin and Combination Therapy Study

JPET #227066

- Investigators (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. *Urology* 61(1):119-26.
- Kojima Y, Sasaki S, Shinoura H, Hayashi Y, Tsujimoto G, and Kohri K (2006) Quantification of alpha1-adrenoceptor subtypes by real-time RTPCR and correlation with age and prostate volume in benign prostatic hyperplasia patients. *Prostate* 66: 761-767.
- Kojima Y, Sasaki S, Oda N, Koshimizu TA, Hayashi Y, Kiniwa M, Tsujimoto G, Kohri K (2009a) Prostate growth inhibition by subtype-selective alpha1-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. *Prostate* 69: 1521-1528.
- Kojima Y, Sasaki S, Hayashi Y, Tsujimoto G, Kohri K (2009b) Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine. *Nat Clin Pract Urol*. 6(1):44-53.
- Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson KE (2011) Relation between expression of  $\alpha(1)$ -adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. *Scand J Urol Nephrol* 45: 15-19.
- Kyprianou N, Vaughan TB, and Michel MC (2009) Apoptosis induction by doxazosin and other quinazoline  $\alpha 1$ -adrenoceptor antagonists: a new mechanism for cancer treatment? *Naunyn-Schmied Arch Pharmacol* 380: 473-477
- Leopoldo M, Berardi F, Colabufo NA, Contino M, Lacivita E, Perrone R, Tortorella V (2004) Studies on 1-arylpiperazine derivatives with affinity for rat 5-HT7 and 5-HT1A receptors. *J Pharm Pharmacol* 56: 247-255.
- Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C,

JPET #227066

- Machi M, Narayan P, Padley RJ (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. *N Engl J Med* **335**(8):533-9.
- Liebmann C (2011) EGF receptor activation by GPCRs: An universal pathway reveals different versions. *Mol Cell Endocrinol* **331**: 222-231.
- Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* **193**: 265-275.
- Lu J-J, Pan W, Hu Y-J, and Wang Y-T (2012) Multi-Target Drugs: The Trend of Drug Research and Development. *PLoS ONE* **7**(6): e40262
- Malloy BJ, Price DT, Price RR, Bienstock AM, Dole MK, Funk BL, Rudner XL, Richardson CD, Donatucci CF, and Scwinn DA (1998) Alpha1-adrenergic receptor subtypes in human detrusor. *J Urol* **160**: 937-943
- McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, And Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. *N Engl J Med* **349**: 2387-2398.
- McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, Foster HE Jr, Gonzalez CM, Kaplan SA, Penson DF, Ulchaker JC, Wei JT (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. *J Urol* **185**: 1793-1803.
- Michel MC, Hanft G, and Gross G (1994). Radioligand binding studies of alpha 1-



JPET #227066

adrenoceptor subtypes in rat heart. *Br J Pharmacol* **111**: 533–538.

Michel MC, Vrydag W (2006)  $\alpha$ 1-,  $\alpha$ 2- and  $\beta$ -adrenoceptors in the urinary bladder, urethra and prostate. *Br J Pharmacol* **147**: S88-S119.

Michel MC (2010). The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction:  $\alpha$ -blockers in the treatment of male voiding dysfunction – how do they work and why do they differ in tolerability? *J Pharmacol Sci* **112**: 151–157.

Morelli MB, Amantini C, Nabissi M, Liberati S, Cardinali C, Farfariello V, Tomassoni D, Quaglia W, Piergentili A, Bonifazi A, Del Bello F, Santoni M, Mammana G, Servi L, Filosa A, Gismondi A, and Santoni G (2014) Cross-talk between  $\alpha$ 1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation. *BMC Cancer* **14**:921. doi: 10.1186/1471-2407-14-92.

Morphy R, Kay C, and Rankovic Z (2004) From magic bullets to designed multiple ligands. *Drug Discov Today* **9**: 641-651.

Nasu K, Koriyama N, Kawabe K, Tsujimoto G, Murai M, Tanaka T, Yano J (1996). Quantification and distribution of  $\alpha$ 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. *Br J Pharmacol* **119**: 797–803.

Neves GA, Menegatti R, Antonio CB, Graziottin LR, Vieira RO, Rates SMK, Noël F, Barreiro EJ, Fraga CA (2010) Searching for multitarget antipsychotics: discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors. *Bioorg Med Chem* **18**: 1925-1935.

Nickel JC (2003) Benign Prostatic Hyperplasia: Does Prostate Size Matter? *Rev Urol* **5** (suppl 4): S12-S17.

JPET #227066

- Nickel JC (2006) BPH: costs and treatment outcomes. *Am J Manag Care* **12**:S141-S148.
- Noble AJ, Chess-Williams R, Couldwell C, Furukawa K, Uchiyama T, Korstanje C, Chapple CR (1997) The effects of tamsulosin, a high affinity antagonist at functional alpha 1A- and alpha-1D adrenoceptor subtypes. *Br J Pharmacol* **120**: 231–238.
- Noël F, Pompeu TE, and Moura BC (2014) Functional binding assays for estimation of The intrinsic efficacy of ligands at the 5-HT1A receptor: application for screening drug candidates. *J Pharmacol Toxicol Methods* **70**: 12-18.
- Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'dow J, Nordling J, de la Rosette JJ, European Association of Urology (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. *Eur Urol* **64**: 118–140.
- Ohmura T, Muramatsu I (1995) Two distinct  $\alpha_1$ -adrenoceptor subtypes in rabbit liver: a binding study. *Br J Pharmacol* **116**: 2591-2596.
- Perabo FG (2012) Drug development for LUTS - the challenge for industry. *Drug Disc Today: Ther Strategies* **9**: e5–e14.
- Pradidarcheep W, Stallen J, Labruyère WT, Dabhoiwala NF, Michel MC, Lamers WH (2009) Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. *Naunyn Schmiedebergs Arch Pharmacol.* **379**:397-402.
- Priest B, Bell IM, Garcia M (2008) Role of hERG potassium channel assays in drug development. *Channels* **2**: 97-93.
- Peters JU (2013) Polypharmacology - foe or friend? *J Med Chem* **56**: 8955-8971.
- Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, and Lefkowitz RJ (1993)

JPET #227066

Identification, quantification and localization of mRNA for three distinct  $\alpha_1$  adrenergic receptor subtypes in human prostate. *J Urol* **150**: 546-551.

Pulito VL, Li X, Varga SS, Mulcahy LS, Clark KS, Halbert SA, Reitz AB, Murray WV, Jolliffe LK (2000) An investigation of the uroselective properties of four novel  $\alpha_1(1a)$ -adrenergic receptor subtype-selective antagonists. *J Pharmacol Exp Ther* **294**: 224-229.

Roehrborn CG (2008) Pathology of benign prostatic hyperplasia. *Int J Impot Res* **20**: S11-S18.

Romeiro LA, da Silva Ferreira M, da Silva LL, Castro HC, Miranda AL, Silva CL, Noël F, Nascimento JB, Araújo CV, Tibiriçá E, Barreiro EJ, Fraga CA (2011) Discovery of LASSBio-772, a 1,3-benzodioxole N-phenylpiperazine derivative with potent  $\alpha_1A/D$ -adrenergic receptor blocking properties. *Eur J Med Chem* **46**: 3000-3012.

Rudner XL, Berkowitz DE, Booth JV, Funk BL, Cozart KL, D'Amico EB, El-Moalem H, Page SO, Richardson CD, Winters B, Marucci L, Schwinn DA (1999) Subtype specific regulation of human vascular  $\alpha_1$ -adrenergic receptors by vessel bed and age. *Circulation* **100**: 2336-2343.

Sciarra A, Mariotti G, Salciccia S, Autran Gomez A, Monti S, Toscano V, Di Silverio F (2008) Prostate growth and inflammation. *J Steroid Biochem Mol Biol* **108**: 254-260.

Takei R-I, Ikegaki I, Shibata K, Tsujimoto G, Asano T (1999) Naftopidil, a novel  $\alpha_1$ -adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human  $\alpha_1$ -adrenoceptors. *Jpn J Pharmacol* **79**: 447-454.

Tarle M, Spajic B, Kraljic I, and Kusic Z (2009) Continuous finasteride therapy for

JPET #227066

benign prostate hypertrophy upgrades both neuroendocrine differentiation and aggressive prostate cancer. *Anticancer Res* **29**: 1797-17801.

Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, Godinot N, Robertson CN, Saussy D (1995) The  $\alpha_{1C}$ -adrenoceptor in human prostate: Cloning, functional expression, and localization to specific prostatic cell types. *Br J Pharmacol* **115**: 1475-1485.

Vázquez-Prado J, Medina LC, García-Sáinz JA (1997) Activation of endothelin ETA receptors induces phosphorylation of alpha1b-adrenoreceptors in Rat-1 fibroblasts. *J Biol Chem* **272**: 27330-27337.

Williams T J, Blue D R, Daniels DV, Davis B, Elworthy T, Gever JR, Kava MS, Morgans D, Padilla F, Tassa S, Vimont RL, Chapple CR, Chess-Williams R, Eglen RM, Clarke DE, Ford AP (1999) In vitro alpha1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel alpha1A-adrenoceptor selective antagonists. *Br J Pharmacol* **127**: 252-258.

Zhang H, Chalothorn D, Jackson LF, Lee DC, and Faber JE (2004) Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. *Circ Res* **95**: 989-997.

JPET #227066

### Footnotes

This work was supported by the CNPq [455436/2014-2; 307668/2012-6; 473053/2004-7], FAPERJ [E-26/110.378/2014], CONACyT [177556] and DGAPA-UNAM [IN200812-IN200915]. hERG K<sup>+</sup> channel (performed by CEREP, France), rat IUP and blood pressure assays (dose-response curves) were sponsored by Biozeus Desenvolvimento de Produtos Biofarmacêuticos S.A. (Brazil) [BZ073PHA].

<sup>2</sup> For reprint requests:

Claudia Lucia Martins Silva,

Adress: Av Carlos Chagas Filho, 373. Zip code 21941-599, Rio de Janeiro, Brazil.

e-mail: [cmartins@farmaco.ufrj.br](mailto:cmartins@farmaco.ufrj.br); [silva.claudiamartins.ufrj@gmail.com](mailto:silva.claudiamartins.ufrj@gmail.com)

JPET #227066

### Legends for Figures

Figure 1. Effect of LDTs treatment on phenylephrine-induced contraction of rat prostate (A) and aorta (B), and on [<sup>3</sup>H]-prazosin binding to rat liver membranes (C). These tissues are enriched in the  $\alpha_1$ -adrenoceptor subtypes  $\alpha_{1A}$  (prostate),  $\alpha_{1D}$  (aorta) and  $\alpha_{1B}$  (liver). During isometric contraction assays mediated by  $\alpha_{1A}$ - and  $\alpha_{1D}$ -adrenoceptors, tissues were pre-incubated with test compounds for 60 min before stimulation with phenylephrine. Note that the error bars showed here represent the SEM (instead of SD) of the means of 6-9 experiments using tissue samples from different animals. Competition binding data represent averaged curves from 3 to 5 independent experiments performed in triplicate.

Figure 2. Inhibition of  $\alpha_{1D}$ -adrenoceptor- and 5-HT<sub>1A</sub> receptor-dependent prostate cell growth by LDTs. Trypan blue exclusion assays were performed using prostate cells from benign prostate hyperplasia (BPH) patients. BMY7378 (50 nM) and *p*-MPPF (50 nM, B) were used as selective antagonists of  $\alpha_{1D}$ -adrenoceptors (A) and 5-HT<sub>1A</sub> receptors (B), respectively. PHE = phenylephrine. The mean number of cells in the control condition (vehicle) was  $1.13 \times 10^5$  cells. Data were expressed as mean and SD. *n* = 3-4 different cell cultures using cells from three donors. Assays performed in triplicates. (A)  $F_{9,28} = 5.086$ ,  $P = 0.0004$ . (B)  $F_{7,21} = 12.30$ ,  $P < 0.0001$ . \* $P < 0.05$ , \*\* $P < 0.01$  and \*\*\* $P < 0.001$  vs. the agonists (One-way analysis of variance (ANOVA) followed by the *post-hoc* Dunnett's test).

JPET #227066


Figure 3. Effect of LDT3 treatment on phenylephrine (PHE)-induced intracellular calcium elevation in Rat-1 fibroblasts transfected with the human  $\alpha_{1D}$ -adrenoceptor. The sharp increase in the intracellular calcium concentration ( $[Ca^{2+}]_i$ ) induced by 100  $\mu$ M PHE (A; vehicle) was attenuated by treatment with 10 and 100 nM LDT3 (B and C, respectively).




Figure 4. Effects of LDT3 and LDT5 on intraurethral pressure modulation by phenylephrine. (A) Dose-response curve for the effect of phenylephrine (PHE, i.v.) on rat intraurethral pressure (IUP). The error bars showed here represent the SEM (instead of SD) of the mean (n=7). (B) Effect of PHE (30  $\mu$ g.kg<sup>-1</sup>) on IUP in the absence (white bar) or presence of pre-treatment with a single dose of LDT3 or LDT5 (0.1  $\mu$ g.kg<sup>-1</sup>, i.v.) (black bars). Data were expressed as mean and SD, n = 3-5.  $F_{4,20} = 64.82$ ,  $P < 0.0001$ . \*\*\* $P < 0.001$  vs. PHE alone; \*\*  $P < 0.01$  PHE after LDT3 vs. PHE after LDT5 (ANOVA followed by *post hoc* Newman-Keuls test). (C) Dose-response curves of LDT5 (n = 4) or tamsulosin (n = 3) on IUP. The error bars showed here represent the SEM (instead of SD) of the mean. (D) Effect of different doses of LDT5 on basal blood pressure. Data were expressed as mean and SD, n = 3-6.  $F_{4,19} = 10.97$ ,  $P < 0.0001$ . \*\*\* $P < 0.001$  vs. vehicle (One-way analysis of variance (ANOVA) followed by the *post-hoc* Dunnett's test).

JPET #227066

**Tables**

Table 1. Chemical structure of the *N*-phenylpiperazine derivatives LDT3, LDT5, LDT8 and LDT66.



LDT	R <sub>1</sub>	R <sub>2</sub>	Name
3		-CH <sub>3</sub>	1-(2-methoxyphenyl)-4-[2-(3-methoxyphenyl)ethyl]piperazine
5		-CH <sub>3</sub>	1-(2-methoxyphenyl)-4-[2-(3,4-dimethoxyphenyl)ethyl]piperazine
8		-CH <sub>2</sub> CH <sub>3</sub>	1-(1,3-benzodioxol-5-ylethyl)-4-ethoxyphenyl)piperazine
66 <sup>*</sup>	-(CH <sub>2</sub> ) <sub>5</sub> CH <sub>3</sub>	-CH <sub>3</sub>	1-(2-methoxyphenyl)-4-hexylpiperazine

<sup>\*</sup> from Chagas-Silva et al., 2014, with permission



JPET #227066

**Table 2.** Affinity of *N*-phenylpiperazine derivatives for native rat  $\alpha_{1D}$ - and  $\alpha_{1A}$ -adrenoceptors.

receptor	compound	Control	Treated	$\log K_B \pm SD$	$K_B$	n
		EC <sub>50</sub> ( $\mu$ M)	EC <sub>50</sub> ( $\mu$ M)	(M)	(nM)	
		[log EC <sub>50</sub> $\pm$ SD]	[log EC <sub>50</sub> $\pm$ SD]			
$\alpha_{1A}$	<b>LDT3</b>	0.24 [-6.62 $\pm$ 0.19]	1.2 [-5.92 $\pm$ 0.20]	- 8.58 $\pm$ 0.28 <sup>***</sup>	<b>2.62</b>	7
	<b>LDT5</b>	0.14 [-6.86 $\pm$ 0.27]	7.9 [-5.10 $\pm$ 0.37]	- 9.74 $\pm$ 0.35	<b>0.18</b>	13
	<b>LDT8</b>	0.25 [-6.60 $\pm$ 0.24]	14.8 [-4.83 $\pm$ 0.27]	- 9.76 $\pm$ 0.32	<b>0.17</b>	10
	<b>LDT66<sup>a</sup></b>	-	-		<b>3.4<sup>&amp;</sup></b>	-
	<b>tamsulosin<sup>a</sup></b>	-	-	- 10.08 $\pm$ 0.04	<b>0.08</b>	3
$\alpha_{1D}$	<b>LDT3<sup>b</sup></b>	0.15 [-6.87 $\pm$ 0.23]	3.55 [-5.45 $\pm$ 0.24]	-8.71 $\pm$ 0.10 <sup>*</sup>	<b>1.95</b>	6
	<b>LDT5<sup>c</sup></b>	0.08 [-7.12 $\pm$ 0.23]	1.34 [-5.87 $\pm$ 0.23]	-9.23 $\pm$ 0.08 <sup>***</sup>	<b>0.59</b>	8
	<b>LDT8<sup>c</sup></b>	0.07 [-7.14 $\pm$ 0.09]	4.58 [-5.34 $\pm$ 0.14]	-9.75 $\pm$ 0.16 <sup>***</sup>	<b>0.18</b>	9
	<b>LDT66<sup>a</sup></b>	-	-		<b>2.18<sup>&amp;</sup></b>	-
	<b>BMY 7378<sup>a</sup></b>	-	-	-8.53 $\pm$ 0.13	<b>3.03</b>	5
	<b>tamsulosin<sup>a</sup></b>	-	-	9.99 $\pm$ 0.1	<b>0.1</b>	3

<sup>a</sup>Data from Chagas-Silva et al., 2014 used for comparison (with permission). <sup>&</sup> Calculated from pA<sub>2</sub> values by Schild regression of mean curves (Chagas-Silva et al., 2014 used for comparison (with permission)).

JPET #227066

For  $\alpha_{1A}$ -adrenoceptors, the  $EC_{50}$  and  $K_B$  values were estimated using isomeric contraction assays of rat prostate stimulated with phenylephrine, in the absence or presence of 10 nM of the antagonist. Tamsulosin (10 nM) was used as control.

For  $\alpha_{1D}$ -adrenoceptors,  $EC_{50}$  and  $K_B$  values were estimated using isomeric contraction assays of rat aorta stimulated with phenylephrine in the absence or presence of 50 nM (<sup>b</sup>), or 10 nM (<sup>c</sup>) of the antagonist. BMY 7378 (10 nM) was used as a selective antagonist of  $\alpha_{1D}$ -adrenoceptors.

Log  $K_B$  values were calculated individually.

$F_{3,29} = 27.10$ ,  $P < 0.0001$  for  $\alpha_{1A}$ -adrenoceptors. \*\*\*  $P < 0.001$  compared to tamsulosin (one way ANOVA followed by a *post-hoc* Dunnett's test)

$F_{3,24} = 169.7$ ,  $P < 0.0001$  for  $\alpha_{1D}$ -adrenoceptor. \*  $P < 0.05$ , \*\*\*  $P < 0.001$  compared to BMY 7378 (one way ANOVA followed by a *post-hoc* Dunnett's test).

JPET #227066

**Table 3.** Affinity of LDT3, LDT5 and LDT8 for rat 5-HT<sub>1A</sub> receptors.

<b>Compound</b>	<b>K<sub>i</sub> High, nM (n)</b>	<b>K<sub>i</sub> Low, nM (n)</b>	<b>K<sub>i</sub> Low/K<sub>i</sub> High</b>
	<b>[pK<sub>i</sub> ± SD]</b>	<b>[pK<sub>i</sub> ± SD]</b>	<b>[95% C.I.]</b>
<b>LDT3</b>	1.12 (4)	1.73 (3)	1.53
	[8.95 ± 0.07] ***	[8.76 ± 0.19]*	[1.02-2.81]
<b>LDT5</b>	2.51 (4)	6.91 (3)	2.75
	[8.60 ± 0.05] ***	[8.16 ± 0.13] ***	[1.68-4.50]
<b>LDT8</b>	0.009 (2)	0.62 (3)	66.9
	[11.05 ± 0.03]	[9.21 ± 0.07]	[45.0-99.8]
<b>LDT66<sup>a</sup></b>	5.9 (4)	10.2 (4)	1.71
	[8.23 ± 0.3] ***	[7.99 ± 0.1] ***	[0.32-9.20]
<b>5-HT<sup>a</sup></b>	3.02 (3)	213 (6)	76.8
	[8.52 ± 0.03]	[6.67 ± 0.15]	[40.5-146]

K<sub>i</sub> values were determined in competition binding assays with the agonist [<sup>3</sup>H]8-OH-DPAT (K<sub>i</sub> High) or antagonist [<sup>3</sup>H]p-MPPF (in the presence of high GTP; K<sub>i</sub> Low), using membrane preparations of rat hippocampus. pK<sub>i</sub> values (*i.e.*, -log K<sub>i</sub>) were expressed as arithmetic means and SD of (n) experiments. The K<sub>i</sub> Low/K<sub>i</sub> High ratio is an estimate of the intrinsic activity towards 5-HT<sub>1A</sub> receptors, where values significantly higher than 1 indicate agonist activity (5-HT, was used as an example of full agonist), while values close to 1 indicate antagonist activity. The 95% confidence intervals (C.I.) of the K<sub>i</sub> ratios were calculated as previously described (Noël et al., 2014).

<sup>a</sup> Data from Chagas-Silva et al., 2014 with permission.

F<sub>3,10</sub> = 1471, P < 0.0001 for K<sub>i</sub> high. \*\*\* P < 0.001 compared to LDT8 (one way ANOVA for LDTs followed by a *post-hoc* Dunnett's test).

F<sub>3,9</sub> = 55.97, P < 0.0001 for K<sub>i</sub> low. \* P < 0.05, \*\*\* P < 0.001 compared to LDT8 (one way ANOVA for LDTs followed by a *post-hoc* Dunnett's test).

# Rat prostate

## A




Fig 1A

B

Rat aorta




Fig. 1B




Fig. 1C




Fig. 2A







Fig. 2B





**Fig 3**





Fig. 4A



<b>PHE 30 <math>\mu\text{g}\cdot\text{kg}^{-1}</math></b>	+	-	+	-	+
<b>LDT3 0.1 <math>\mu\text{g}\cdot\text{kg}^{-1}</math></b>	-	+	+	-	-
<b>LDT5 0.1 <math>\mu\text{g}\cdot\text{kg}^{-1}</math></b>	-	-	-	+	+

Fig. 4B




Fig. 4C




Fig 4D